微导管超选择化疗栓塞治疗肝癌的临床研究

Clinical research of microcatheter in super select transcatheter arterial chemoembolization therapy for liver cancer

目的评估微导管超选择化疗栓塞在原发性肝癌(hepatocellular carcinoma,HCC)治疗中的价值。方法回顾分析2010年1月至2011年3月收治的行普通选择性化疗栓塞和微导管超选择性化疗栓塞的141例HCC患者的临床资料,比较两组的疗效及不良反应的发生情况。结果微导管栓塞组提高了插管成功率(P<0.05),减轻了化疗栓塞不良反应及肝功能损害(P<0.05),患者的6个月、1年带瘤生存率明显提高(P<0.05)。结论微导管超选择性化疗栓塞术优势显著,有望替代经普通导管肝内动脉化疗栓塞术,是肝癌综合治疗中不可缺少的治疗手段。

Objective To evaluate the treatment value of microcatheter in chemoembolization in hepatocellular carcinoma.Methods The data of 141 cases of HCC who select conventional embolization therapy or microcatheter embolization therapy during January 2010 to March 2011 were summarized,and compared with curative effect and adverse events of two groups.Results The microcatheter embolization therapy group improved the success rate of intubation（P0.05）,reduced adverse reactions and chemotherapy embolism liver damage （P0.05）,and improved patients with tumor 1 year survival rates obviously （P0.05）.Conclusions The microcatheter embolization therapy display significant advantages,and this technique is expected to replace conventional embolization therapy.It is indispensable in comprehensive therapy of HCC.